Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy

Immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy by restoring the host antitumor immune response. Since 2011, various ICIs have been approved for the treatment of cancers, which has led to unprecedented prolongation of the survival time for some patients. Although ICIs ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Weiwei, Liu, Chaoqun, Wang, Hui, Xu, Lijun, Zhou, Jueyu, Li, Sihua, Cheng, Yu, Zhou, Rui, Zhao, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508382/
https://www.ncbi.nlm.nih.gov/pubmed/36187919
http://dx.doi.org/10.1016/j.csbj.2022.09.017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508382/
https://www.ncbi.nlm.nih.gov/pubmed/36187919
http://dx.doi.org/10.1016/j.csbj.2022.09.017

Ejemplares similares